Derivative exercise or conversion — not an open-market buy.
Traded May 7, 2026 · Filed May 11, 2026
The boss of ResMed| sold $1.04M of ResMed| shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,037,233
Shares × reported transaction price
7 days after results of Apr 30, 2026, 61 days before results of Jul 7, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $206.89 on May 7, 2026, within 1% of its 52-week low, after a 9% drop over the previous 30 trading days
52-week range $205.02 (May 1, 2026) to $293.73 (Aug 22, 2025), 2% of the way up, from 251 adjusted closes. 30 trading days earlier: $226.31 on Mar 25, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.0% | -0.6% | +2.6% |
| 30 days | -5.6% | -0.1% | -5.5% |
| 90 days | +8.0% | +4.7% | +3.3% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.